Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -6.28% is 165% below its 5-year average of 9.65%, near the low end of its 5-year range (-6.28%–17.23%).
As of the fiscal period ended Saturday, December 27, 2025. 194.84% below its 12-month average of -2.13%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
-6.28%
RETURN ON EQUITY (ROE) AVG TTM
-2.13%
RETURN ON EQUITY (ROE) AVG 3Y
6.32%
RETURN ON EQUITY (ROE) AVG 5Y
9.65%
RETURN ON EQUITY (ROE) AVG 10Y
12.84%
RETURN ON EQUITY (ROE) AVG 15Y
16.72%
RETURN ON EQUITY (ROE) AVG 20Y
12.31%
CURRENT VS TTM AVG
-194.84%
CURRENT VS 3Y AVG
-199.37%
CURRENT VS 5Y AVG
-165.04%
CURRENT VS 10Y AVG
-148.92%
CURRENT VS 15Y AVG
-137.57%
CURRENT VS 20Y AVG
-151.00%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-157.67%
vs the sector median at left
Charles River Laboratories International, Inc.
Market Cap
$11.20B
Return on Equity (ROE)
-6.28%
TTM Avg
-2.13%
3Y Avg
6.32%
5Y Avg
9.65%
Market Cap
$11.29B
Return on Equity (ROE)
5.25%
TTM Avg
5.98%
3Y Avg
10.62%
5Y Avg
11.34%
Market Cap
$11.45B
Return on Equity (ROE)
23.25%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$10.37B
Return on Equity (ROE)
-87.68%
TTM Avg
-49.03%
3Y Avg
-18.16%
5Y Avg
-9.00%
Market Cap
$12.11B
Return on Equity (ROE)
9.77%
TTM Avg
10.54%
3Y Avg
10.84%
5Y Avg
19.93%
Market Cap
$10.21B
Return on Equity (ROE)
-0.17%
TTM Avg
18.91%
3Y Avg
22.60%
5Y Avg
24.60%
Market Cap
$10.20B
Return on Equity (ROE)
20.19%
TTM Avg
18.80%
3Y Avg
15.17%
5Y Avg
15.31%
Market Cap
$12.55B
Return on Equity (ROE)
3.35%
TTM Avg
3.59%
3Y Avg
3.35%
5Y Avg
7.68%
Market Cap
$9.77B
Return on Equity (ROE)
12.09%
TTM Avg
11.88%
3Y Avg
12.69%
5Y Avg
13.50%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | $11.20B | -6.28% | -2.13% | 6.32% | 9.65% |
| Bio-Techne Corporation (TECH)vs › | $11.29B | 5.25% | 5.98% | 10.62% | 11.34% |
| Insulet Corp. (PODD)vs › | $11.45B | 23.25% | 25.41% | 19.99% | 14.02% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Align Technology, Inc. (ALGN)vs › | $12.11B | 9.77% | 10.54% | 10.84% | 19.93% |
| Molina Healthcare, Inc. (MOH)vs › | $10.21B | -0.17% | 18.91% | 22.60% | 24.60% |
| Universal Health Services, Inc. (UHS)vs › | $10.20B | 20.19% | 18.80% | 15.17% | 15.31% |
| Revvity, Inc. (RVTY)vs › | $12.55B | 3.35% | 3.59% | 3.35% | 7.68% |
| Henry Schein, Inc. (HSIC)vs › | $9.77B | 12.09% | 11.88% | 12.69% | 13.50% |
| Baxter International Inc. (BAX)vs › | $13.52B | -17.13% | -12.46% | -8.76% | -1.37% |
ROE
-6.3%
ROA
-2.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-27 | -4.56% |
| 2024-12-28 | 0.30% |
| 2023-12-31 | 13.20% |
| 2022-12-31 | 16.34% |
| 2021-12-31 | 15.42% |
| 2020-12-31 | 17.23% |
| 2019-12-31 | 15.42% |
| 2018-12-31 | 17.18% |
| 2017-12-31 | 11.80% |
| 2016-12-31 | 18.50% |
| 2015-12-31 | 20.37% |
| 2014-12-31 | 18.85% |
| 2013-12-31 | 16.04% |
| 2012-12-31 | 16.19% |
| 2011-12-31 | 20.78% |
| 2010-12-31 | -48.98% |
| 2009-12-31 | 8.33% |
| 2008-12-31 | -43.52% |
| 2007-12-31 | 8.30% |
| 2006-12-31 | -3.50% |
| 2005-12-31 | 7.77% |
| 2004-12-31 | 6.10% |
| 2003-12-31 | 17.25% |
| 2002-12-31 | 14.03% |
| 2001-12-31 | 12.23% |
| 2000-12-31 | -9.60% |
| 1999-12-31 | -15.55% |
| 1998-12-31 | 13.89% |
